<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01340794</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2011-02588</org_study_id>
    <secondary_id>NCI-2011-02588</secondary_id>
    <secondary_id>CDR0000699430</secondary_id>
    <secondary_id>MAYO-MC107B</secondary_id>
    <secondary_id>MC107B</secondary_id>
    <secondary_id>8783</secondary_id>
    <secondary_id>N01CM00039</secondary_id>
    <secondary_id>N01CM00099</secondary_id>
    <secondary_id>N01CM62205</secondary_id>
    <secondary_id>P30CA015083</secondary_id>
    <nct_id>NCT01340794</nct_id>
  </id_info>
  <brief_title>Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma</brief_title>
  <official_title>A Phase 2 Study of Pazopanib (GW786034) in Patients With Advanced and Progressive Malignant Pheochromocytoma or Paraganglioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well pazopanib hydrochloride works in treating patients with&#xD;
      advanced or progressive malignant pheochromocytoma or paraganglioma. Pazopanib hydrochloride&#xD;
      may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and&#xD;
      by blocking blood flow to the tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the anti-tumor activity (in terms of the tumor response rate using the Response&#xD;
      Evaluation Criteria in Solid Tumors [RECIST] criteria) of pazopanib (pazopanib hydrochloride)&#xD;
      (GW786034) in patients with advanced malignant pheochromocytomas and paragangliomas.&#xD;
&#xD;
      SECONDARY OBJEC TIVES:&#xD;
&#xD;
      I. To assess safety profile of pazopanib. II. To assess duration of tumor response. III. To&#xD;
      assess time to treatment failure. IV. To assess progression-free survival time. V. To assess&#xD;
      overall survival time.&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. For patients with secretory tumors, to examine changes in urinary catecholamine and/or&#xD;
      metanephrine levels.&#xD;
&#xD;
      II. For patients with secretory tumors, to examine whether pazopanib-induced changes in&#xD;
      urinary catecholamine and/or metanephrine levels during the first cycle of treatment may be&#xD;
      associated with objective tumor response.&#xD;
&#xD;
      III. To examine associations between tumor response and somatic mutational status in archived&#xD;
      tumors, or germline mutational status in patient's peripheral blood mononuclear cells,&#xD;
      (presence of succinate dehydrogenase complex subunit D [SDHD], succinate dehydrogenase&#xD;
      complex subunit B [SDHB], ret proto-oncogene [RET], von Hippel-Lindau tumor suppressor [VHL],&#xD;
      neurofibromatosis type-1).&#xD;
&#xD;
      IV. To examine associations between tumor response and tumor expression levels of angiogenic&#xD;
      and vascular markers including hypoxia inducible factor 1, alpha (HIF-1a), vascular&#xD;
      endothelial growth factor receptor (VEGF-R) (total and phospho-) and microvessel density in&#xD;
      archival tumor tissue.&#xD;
&#xD;
      IV. To examine whether the extent of tumor response/regression may be correlated with plasma&#xD;
      pazopanib (GW786034) concentration achieved after the third cycle (first cycle after run-in&#xD;
      cycles) of pazopanib (GW786034) therapy.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive pazopanib hydrochloride orally (PO) once daily (QD) on days 1-28 (days 1-14&#xD;
      of courses 1 and 2). Courses repeat every 28 days in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      Patients undergo urine and blood sample collection at baseline and periodically during study&#xD;
      for correlative studies.&#xD;
&#xD;
      After completion of study therapy, patients are followed up every 3-6 months for up to 5&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow Accrual&#xD;
  </why_stopped>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate (RR) (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.1</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Response and progression are evaluated in this study using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1) Ninety-five percent confidence intervals for the true response proportion was calculated using the exact binomial test.&#xD;
Complete Response (CR): All of the following must be true:&#xD;
Disappearance of all target and non-target lesions.&#xD;
Each lymph node must have reduction in short axis to &lt;1.0 cm.&#xD;
Partial Response (PR):&#xD;
At least a 30% decrease in PBSD (sum of the longest diameter for all target lesions plus the sum of the short axis of all the target lymph nodes at current evaluation) taking baseline measures as reference.&#xD;
Overall Response (OR) was calculated by summing the number of patients with a CR or PR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Tumor Response</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Defined for all patients whose tumor met the criteria of CR or PR (using the RECIST criteria) as the date at which the patient's objective status is first noted to be either a CR or PR to the date progression is documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Time</measure>
    <time_frame>The time from registration to death due to any cause, assessed up to 5 years</time_frame>
    <description>Overall survival time is defined as the time from registration to death due to any cause and will be estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival Time</measure>
    <time_frame>The time from registration to documentation of disease progression or death, whichever occurs first, assessed up to 5 years</time_frame>
    <description>Progression-free survival is defined as the time from registration to documentation of disease progression. If a patient dies without a documentation of disease progression, the patient will be considered to have had tumor progression at the time of their death unless there is sufficient documented evidence to conclude no progression occurred prior to death. Progression-free survival time will be estimated using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure</measure>
    <time_frame>Up to 5 years from registration</time_frame>
    <description>The time from the date of registration to the date at which the patient is removed from treatment due to progression, toxicity, or refusal, assessed up to 5 years.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Extra-Adrenal Paraganglioma</condition>
  <condition>Metastatic Adrenal Gland Pheochromocytoma</condition>
  <condition>Paraganglioma</condition>
  <condition>Recurrent Adrenal Gland Pheochromocytoma</condition>
  <arm_group>
    <arm_group_label>Treatment (pazopanib hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive pazopanib hydrochloride PO QD on days 1-28 (days 1-14 of courses 1 and 2). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (pazopanib hydrochloride)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib Hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (pazopanib hydrochloride)</arm_group_label>
    <other_name>GW786034B</other_name>
    <other_name>Votrient</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed malignant secretory or non-secretory&#xD;
             pheochromocytoma or paraganglioma that is unresectable and deemed inappropriate for&#xD;
             alternative local regional therapeutic approaches&#xD;
&#xD;
          -  Objective evidence of tumor progression =&lt; 185 days prior to registration as assessed&#xD;
             by:&#xD;
&#xD;
               -  Unequivocal progression of objectively measured disease on successive appropriate&#xD;
                  imaging (e.g. computed tomography [CT] scan); in cases of uncertainty of tumor&#xD;
                  progression, the principal investigator of the study will be available to assist&#xD;
                  in decisions&#xD;
&#xD;
          -  Measurable disease defined as:&#xD;
&#xD;
               -  At least one non-nodal lesion whose longest diameter can be accurately measured&#xD;
                  as &gt;= 2.0 cm with chest x-ray, or as &gt;= 1.0 cm with CT scan, CT component of a&#xD;
                  positron emission tomography (PET)/CT, or magnetic resonance imaging (MRI);&#xD;
                  and/or&#xD;
&#xD;
               -  A lymph node whose short axis must be &gt; 1.5 cm when assessed by CT scan (CT scan&#xD;
                  slice thickness recommended to be no greater than 5 mm)&#xD;
&#xD;
               -  Note: Tumor lesions in a previously irradiated area are not considered measurable&#xD;
                  disease&#xD;
&#xD;
          -  Life expectancy &gt; 24 weeks&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2&#xD;
&#xD;
          -  Leukocytes &gt;= 3,000/uL&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/uL&#xD;
&#xD;
          -  Platelets &gt;= 100,000/uL&#xD;
&#xD;
          -  Hemoglobin &gt;= 9 g/dL (5.6 mmol/L); transfusions not permitted =&lt; 7 days of&#xD;
             registration&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x institutional upper limit of normal (ULN) (except in cases of&#xD;
             Gilbert's syndrome, where indirect bilirubin may be elevated, but the direct bilirubin&#xD;
             remains within 1.5 x ULN)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])&#xD;
             =&lt; 2.5 x ULN&#xD;
&#xD;
          -  NOTE: Subjects who have both bilirubin &gt; ULN and AST/ALT &gt; ULN are not eligible&#xD;
&#xD;
          -  Alkaline phosphatase =&lt; 2.5 x ULN&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 mg/dL (133 umol/L) or within normal institutional limits OR&#xD;
             creatinine clearance &gt;= 50 mL/min/1.73m^2 for subjects with creatinine levels about&#xD;
             institutional normal&#xD;
&#xD;
          -  Urine protein/creatinine ratio =&lt; 1 OR 24-hour urine &lt; 1 gram&#xD;
&#xD;
          -  Prothrombin time (PT)/international normalized ratio (INR)/partial thromboplastin time&#xD;
             (PTT) =&lt; 1.2 x ULN unless a subject is receiving Coumadin and has stable INR which is&#xD;
             in range for the desired level of anticoagulation&#xD;
&#xD;
          -  Blood pressure (BP) &lt; 140 mmHg (systolic) and &lt; 90 mmHg (diastolic); initiation or&#xD;
             adjustment of BP medication is permitted prior to registration provided that the&#xD;
             average of three BP readings at a visit prior to registration is &lt; 140/90 mmHg&#xD;
&#xD;
               -  NOTE: All patients with secretory pheochromocytomas or paragangliomas are&#xD;
                  required to: 1) be evaluated in consultation by a hypertension specialist (at the&#xD;
                  registering institution) with experience in the management of hypertension in the&#xD;
                  setting of catecholamine-secreting tumors (usually an endocrinologist,&#xD;
                  nephrologist, or a cardiologist), and in the setting of hormone-associated&#xD;
                  hypertension 2) receive alpha- and beta-adrenergic blockade for at least 7 days&#xD;
                  prior to initiation of pazopanib (GW786034); the hypertension specialist of&#xD;
                  record for each patient should be committed to following the patient during the&#xD;
                  clinical study with evaluation by said specialist required at all run-in cycle&#xD;
                  evaluations (cycles 1 and 2) and also after the first continuous dosing cycle&#xD;
                  (cycle 3) and thereafter on an as needed basis&#xD;
&#xD;
          -  Negative serum pregnancy test done =&lt; 7 days prior to registration, for women of&#xD;
             childbearing potential only&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
          -  Willingness to donate blood and tissue for correlative marker studies&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any of the following:&#xD;
&#xD;
               -  Pregnant women&#xD;
&#xD;
               -  Nursing women&#xD;
&#xD;
               -  Men or women of childbearing potential who are unwilling to employ adequate&#xD;
                  contraception NOTE: breastfeeding should be discontinued if the mother is treated&#xD;
                  with pazopanib (GW786034)&#xD;
&#xD;
          -  Any of the following:&#xD;
&#xD;
               -  Chemotherapy/systemic therapy =&lt; 4 weeks prior to registration&#xD;
&#xD;
               -  Radiotherapy =&lt; 4 weeks prior to registration&#xD;
&#xD;
               -  Surgery =&lt; 4 weeks prior to registration&#xD;
&#xD;
               -  Nitrosoureas or mitomycin C =&lt; 6 weeks prior to registration&#xD;
&#xD;
               -  Those who have not recovered from adverse events due to agents administered more&#xD;
                  than 4 weeks earlier NOTE: Concurrent therapy with octreotide is allowed&#xD;
                  providing that tumor progression on this therapy has been demonstrated;&#xD;
                  concurrent therapy with bisphosphonates (e.g. zoledronic acid) or denosumab is&#xD;
                  also allowed.&#xD;
&#xD;
        NOTE: An unlimited number of prior chemotherapeutic or biologic therapies for malignant&#xD;
        pheochromocytoma or paraganglioma is permitted; this includes prior anti-angiogenesis&#xD;
        therapies such as tyrosine kinase inhibitors&#xD;
&#xD;
          -  Any other ongoing investigational agents&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to pazopanib (GW786034) or other agents used in the study&#xD;
&#xD;
          -  Any of the following:&#xD;
&#xD;
               -  Corrected QT (QTc) prolongation (defined as a QTc interval &gt;= 500 msecs)&#xD;
&#xD;
               -  Left ventricular ejection fraction (LVEF) &lt; institutional lower limit of normal&#xD;
                  (LLN)&#xD;
&#xD;
               -  Frequent ventricular ectopy&#xD;
&#xD;
               -  Evidence of ongoing myocardial ischemia&#xD;
&#xD;
          -  Receiving prohibited cytochrome P450 (CYP) interactive concomitant medications within&#xD;
             7 days prior to registration&#xD;
&#xD;
          -  Any condition (e.g., gastrointestinal tract disease resulting in an inability to take&#xD;
             oral medication or a requirement for intravenous (IV) alimentation, prior surgical&#xD;
             procedures affecting absorption, or active peptic ulcer disease) that impairs their&#xD;
             ability to swallow and retain pazopanib (GW786034)&#xD;
&#xD;
          -  Receiving any medications or substances with risk of torsades de pointes; note:&#xD;
             medications or substances with risk of torsades de pointes are prohibited; medications&#xD;
             or substances with possible or conditional risk of torsades de pointes may be used&#xD;
             while on study with extreme caution and careful monitoring; patients receiving these&#xD;
             later cautionary agents must be monitored serially with electrocardiogram (ECG) weekly&#xD;
             during the run-in and first cycle of therapy and at each evaluation thereafter NOTE:&#xD;
             These medications should be discontinued or replaced with drugs that do not carry&#xD;
             these risks, if possible&#xD;
&#xD;
          -  Any of the following conditions:&#xD;
&#xD;
               -  Active peptic ulcer disease&#xD;
&#xD;
               -  Known intraluminal bowel metastatic lesions&#xD;
&#xD;
               -  Inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease) or other&#xD;
                  gastrointestinal conditions which increase the risk of perforation&#xD;
&#xD;
               -  History of new abdominal fistula, gastrointestinal perforation or intra-abdominal&#xD;
                  abscess =&lt; 84 days prior to registration; enrollment of patients with&#xD;
                  chronic/canalized fistulous tracts (present for &gt; 84 days) is allowed&#xD;
&#xD;
               -  Serious or non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
               -  History of familial QTc prolongation syndrome&#xD;
&#xD;
          -  Any of the following conditions =&lt; 185 days prior to registration:&#xD;
&#xD;
               -  Cerebrovascular accident (CVA) or transient ischemic attack (TIA)&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
               -  Admission for unstable angina&#xD;
&#xD;
               -  Cardiac angioplasty or stenting&#xD;
&#xD;
               -  Coronary artery bypass graft surgery&#xD;
&#xD;
               -  Pulmonary embolism, untreated deep venous thrombosis (DVT) or DVT which has been&#xD;
                  treated with therapeutic anticoagulation &lt; 42 days&#xD;
&#xD;
               -  Arterial thrombosis&#xD;
&#xD;
               -  Symptomatic peripheral vascular disease&#xD;
&#xD;
               -  Class III or IV heart failure as defined by the New York Heart Association (NYHA)&#xD;
                  functional classification system&#xD;
&#xD;
          -  Hemoptysis in excess of 2.5 mL (1/2 teaspoon) =&lt; 60 days prior to registration&#xD;
&#xD;
          -  Any of the following:&#xD;
&#xD;
               -  Known active and/or untreated brain metastases&#xD;
&#xD;
               -  Brain metastases requiring ongoing therapy (e.g. corticosteroids)&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral&#xD;
             therapy&#xD;
&#xD;
          -  Require heparin other than low-molecular weight heparin&#xD;
&#xD;
          -  Prior use of pazopanib (GW786034)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith Bible</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic Cancer Center P2C</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224-9980</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro-Minnesota NCI Community Oncology Research Program</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chinese University of Hong Kong-Prince of Wales Hospital</name>
      <address>
        <city>Sha Tin</city>
        <zip>OX1 3UJ</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University Hospital Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Singapore</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>April 21, 2011</study_first_submitted>
  <study_first_submitted_qc>April 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2011</study_first_posted>
  <results_first_submitted>March 23, 2016</results_first_submitted>
  <results_first_submitted_qc>June 9, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 21, 2016</results_first_posted>
  <last_update_submitted>September 19, 2017</last_update_submitted>
  <last_update_submitted_qc>September 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pheochromocytoma</mesh_term>
    <mesh_term>Paraganglioma</mesh_term>
    <mesh_term>Carotid Body Tumor</mesh_term>
    <mesh_term>Paraganglioma, Extra-Adrenal</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study opened on 10/3/2011 and enrolled 2 patients prior to temporarily closing on 2/28/2012 due to safety concerns. After review of AEs, an addendum was implemented which instituted changes to treatment administration, namely, 2 - 14 day run-in periods where patients received pazopanib PO days 1-7 and then were assessed for safety.</recruitment_details>
      <pre_assignment_details>A total of seven patients were recruited to this study. One of the 5 patients registered to the study post-addendum cancelled prior to initiating treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment: Pazopanib With no Run-in</title>
          <description>Patients receive 800 mg pazopanib hydrochloride PO QD on days 1-28 of a 28 day cycle.</description>
        </group>
        <group group_id="P2">
          <title>Treatment: Pazopanib Run-in</title>
          <description>Cycle 1:&#xD;
Patients receive 400 mg pazopanib hydrochloride PO QD on days 1-7 of a 14 day cycle.&#xD;
Cycle 2:&#xD;
Patients receive 800 mg pazopanib hydrochloride PO QD on days 1-7 of a 14 day cycle.&#xD;
Cycle 3 and beyond:&#xD;
Patients receive 800 mg pazopanib hydrochloride PO QD on days 1-28 of a 28 day cycle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All 6 patients that began protocol treatment were included in the baseline analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment: Pazopanib Without Run-in</title>
          <description>Patients receive 800 mg pazopanib hydrochloride PO QD on days 1-28 of a 28 day cycle.</description>
        </group>
        <group group_id="B2">
          <title>Treatment: Pazopanib With Run-in</title>
          <description>Cycle 1:&#xD;
Patients receive 400 mg pazopanib hydrochloride PO QD on days 1-7 of a 14 day cycle.&#xD;
Cycle 2:&#xD;
Patients receive 800 mg pazopanib hydrochloride PO QD on days 1-7 of a 14 day cycle.&#xD;
Cycle 3 and beyond:&#xD;
Patients receive 800 mg pazopanib hydrochloride PO QD on days 1-28 of a 28 day cycle.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" lower_limit="39" upper_limit="45"/>
                    <measurement group_id="B2" value="64.5" lower_limit="53" upper_limit="80"/>
                    <measurement group_id="B3" value="57" lower_limit="39" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response Rate (RR) (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.1</title>
        <description>Response and progression are evaluated in this study using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1) Ninety-five percent confidence intervals for the true response proportion was calculated using the exact binomial test.&#xD;
Complete Response (CR): All of the following must be true:&#xD;
Disappearance of all target and non-target lesions.&#xD;
Each lymph node must have reduction in short axis to &lt;1.0 cm.&#xD;
Partial Response (PR):&#xD;
At least a 30% decrease in PBSD (sum of the longest diameter for all target lesions plus the sum of the short axis of all the target lymph nodes at current evaluation) taking baseline measures as reference.&#xD;
Overall Response (OR) was calculated by summing the number of patients with a CR or PR.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>One of the two patients that initiated treatment with no run-in was found to be ineligible for this endpoint, leaving one patient evaluable for this endpoint in this treatment group. For patient confidentiality, results are not entered for endpoints based on 1 patient measures. All 4 patients that initiated treatment with a run-in were evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment: Pazopanib With no Run-in</title>
            <description>Patients receive 800 mg pazopanib hydrochloride PO QD on days 1-28 of a 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Treatment: Pazopanib Run-in</title>
            <description>Cycle 1:&#xD;
Patients receive 400 mg pazopanib hydrochloride PO QD on days 1-7 of a 14 day cycle.&#xD;
Cycle 2:&#xD;
Patients receive 800 mg pazopanib hydrochloride PO QD on days 1-7 of a 14 day cycle.&#xD;
Cycle 3 and beyond:&#xD;
Patients receive 800 mg pazopanib hydrochloride PO QD on days 1-28 of a 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate (RR) (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.1</title>
          <description>Response and progression are evaluated in this study using the international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (version 1.1) Ninety-five percent confidence intervals for the true response proportion was calculated using the exact binomial test.&#xD;
Complete Response (CR): All of the following must be true:&#xD;
Disappearance of all target and non-target lesions.&#xD;
Each lymph node must have reduction in short axis to &lt;1.0 cm.&#xD;
Partial Response (PR):&#xD;
At least a 30% decrease in PBSD (sum of the longest diameter for all target lesions plus the sum of the short axis of all the target lymph nodes at current evaluation) taking baseline measures as reference.&#xD;
Overall Response (OR) was calculated by summing the number of patients with a CR or PR.</description>
          <population>One of the two patients that initiated treatment with no run-in was found to be ineligible for this endpoint, leaving one patient evaluable for this endpoint in this treatment group. For patient confidentiality, results are not entered for endpoints based on 1 patient measures. All 4 patients that initiated treatment with a run-in were evaluable</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Tumor Response</title>
        <description>Defined for all patients whose tumor met the criteria of CR or PR (using the RECIST criteria) as the date at which the patient's objective status is first noted to be either a CR or PR to the date progression is documented.</description>
        <time_frame>Up to 5 years</time_frame>
        <population>One of the two patients that initiated treatment with no run-in was found to be ineligible for this endpoint, leaving one patient evaluable for this endpoint in this treatment group. For patient confidentiality, results are not entered for endpoints based on 1 patient measures. None of the 4 patients that initiated treatment with a run-in responded</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment: Pazopanib Without Run-in</title>
            <description>Patients receive 800 mg pazopanib hydrochloride PO QD on days 1-28 of a 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Treatment: Pazopanib With Run-in</title>
            <description>Cycle 1:&#xD;
Patients receive 400 mg pazopanib hydrochloride PO QD on days 1-7 of a 14 day cycle.&#xD;
Cycle 2:&#xD;
Patients receive 800 mg pazopanib hydrochloride PO QD on days 1-7 of a 14 day cycle.&#xD;
Cycle 3 and beyond:&#xD;
Patients receive 800 mg pazopanib hydrochloride PO QD on days 1-28 of a 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Tumor Response</title>
          <description>Defined for all patients whose tumor met the criteria of CR or PR (using the RECIST criteria) as the date at which the patient's objective status is first noted to be either a CR or PR to the date progression is documented.</description>
          <population>One of the two patients that initiated treatment with no run-in was found to be ineligible for this endpoint, leaving one patient evaluable for this endpoint in this treatment group. For patient confidentiality, results are not entered for endpoints based on 1 patient measures. None of the 4 patients that initiated treatment with a run-in responded</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival Time</title>
        <description>Overall survival time is defined as the time from registration to death due to any cause and will be estimated using the Kaplan-Meier method.</description>
        <time_frame>The time from registration to death due to any cause, assessed up to 5 years</time_frame>
        <population>One of the two patients that initiated treatment with no run-in was found to be ineligible for this endpoint, leaving one patient evaluable for this endpoint in this treatment group. For patient confidentiality, results are not entered for endpoints based on 1 patient measures. All 4 patients that initiated treatment with a run-in were evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment: Pazopanib Without Run-in</title>
            <description>Patients receive 800 mg pazopanib hydrochloride PO QD on days 1-28 of a 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Treatment: Pazopanib With Run-in</title>
            <description>Cycle 1:&#xD;
Patients receive 400 mg pazopanib hydrochloride PO QD on days 1-7 of a 14 day cycle.&#xD;
Cycle 2:&#xD;
Patients receive 800 mg pazopanib hydrochloride PO QD on days 1-7 of a 14 day cycle.&#xD;
Cycle 3 and beyond:&#xD;
Patients receive 800 mg pazopanib hydrochloride PO QD on days 1-28 of a 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Time</title>
          <description>Overall survival time is defined as the time from registration to death due to any cause and will be estimated using the Kaplan-Meier method.</description>
          <population>One of the two patients that initiated treatment with no run-in was found to be ineligible for this endpoint, leaving one patient evaluable for this endpoint in this treatment group. For patient confidentiality, results are not entered for endpoints based on 1 patient measures. All 4 patients that initiated treatment with a run-in were evaluable</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="14.8" lower_limit="7.6" upper_limit="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival Time</title>
        <description>Progression-free survival is defined as the time from registration to documentation of disease progression. If a patient dies without a documentation of disease progression, the patient will be considered to have had tumor progression at the time of their death unless there is sufficient documented evidence to conclude no progression occurred prior to death. Progression-free survival time will be estimated using the Kaplan-Meier method.</description>
        <time_frame>The time from registration to documentation of disease progression or death, whichever occurs first, assessed up to 5 years</time_frame>
        <population>One of the two patients that initiated treatment with no run-in was found to be ineligible for this endpoint, leaving one patient evaluable for this endpoint in this treatment group. For patient confidentiality, results are not entered for endpoints based on 1 patient measures. All 4 patients that initiated treatment with a run-in were evaluable</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment: Pazopanib With no Run-in</title>
            <description>Patients receive 800 mg pazopanib hydrochloride PO QD on days 1-28 of a 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Treatment: Pazopanib Run-in</title>
            <description>Cycle 1:&#xD;
Patients receive 400 mg pazopanib hydrochloride PO QD on days 1-7 of a 14 day cycle.&#xD;
Cycle 2:&#xD;
Patients receive 800 mg pazopanib hydrochloride PO QD on days 1-7 of a 14 day cycle.&#xD;
Cycle 3 and beyond:&#xD;
Patients receive 800 mg pazopanib hydrochloride PO QD on days 1-28 of a 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival Time</title>
          <description>Progression-free survival is defined as the time from registration to documentation of disease progression. If a patient dies without a documentation of disease progression, the patient will be considered to have had tumor progression at the time of their death unless there is sufficient documented evidence to conclude no progression occurred prior to death. Progression-free survival time will be estimated using the Kaplan-Meier method.</description>
          <population>One of the two patients that initiated treatment with no run-in was found to be ineligible for this endpoint, leaving one patient evaluable for this endpoint in this treatment group. For patient confidentiality, results are not entered for endpoints based on 1 patient measures. All 4 patients that initiated treatment with a run-in were evaluable</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="6.5" lower_limit="2.1" upper_limit="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment Failure</title>
        <description>The time from the date of registration to the date at which the patient is removed from treatment due to progression, toxicity, or refusal, assessed up to 5 years.</description>
        <time_frame>Up to 5 years from registration</time_frame>
        <population>One of the two patients that initiated treatment with no run-in was found to be ineligible for this endpoint, leaving one patient evaluable for this endpoint in this treatment group. For patient confidentiality, results are not entered for endpoints based on 1 patient measures. All 4 patients that initiated treatment with a run-in were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment: Pazopanib With no Run-in</title>
            <description>Patients receive 800 mg pazopanib hydrochloride PO QD on days 1-28 of a 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Treatment: Pazopanib Run-in</title>
            <description>Cycle 1:&#xD;
Patients receive 400 mg pazopanib hydrochloride PO QD on days 1-7 of a 14 day cycle.&#xD;
Cycle 2:&#xD;
Patients receive 800 mg pazopanib hydrochloride PO QD on days 1-7 of a 14 day cycle.&#xD;
Cycle 3 and beyond:&#xD;
Patients receive 800 mg pazopanib hydrochloride PO QD on days 1-28 of a 28 day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Failure</title>
          <description>The time from the date of registration to the date at which the patient is removed from treatment due to progression, toxicity, or refusal, assessed up to 5 years.</description>
          <population>One of the two patients that initiated treatment with no run-in was found to be ineligible for this endpoint, leaving one patient evaluable for this endpoint in this treatment group. For patient confidentiality, results are not entered for endpoints based on 1 patient measures. All 4 patients that initiated treatment with a run-in were evaluable.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2.4" lower_limit="0.8" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment: Pazopanib Without Run-in</title>
          <description>Patients receive 800 mg pazopanib hydrochloride PO QD on days 1-28 of a 28 day cycle.</description>
        </group>
        <group group_id="E2">
          <title>Treatment: Pazopanib With Run-in</title>
          <description>Patients receive 800 mg pazopanib hydrochloride PO QD on days 1-28 of a 28 day cycle.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>CPK increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Cardiac troponin I increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>GGT increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Metabolism and nutrition disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 12</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="27" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Anal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="28" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="7" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="12" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="32" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="15" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="19" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="31" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT corrected interval prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hemoglobin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Investigations - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="17" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="28" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="25" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="7" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" events="6" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin hypopigmentation</sub_title>
                <counts group_id="E1" events="33" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="32" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E2" events="15" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Keith Bible, M.D., Ph.D.</name_or_title>
      <organization>Mayo Clinic Cancer Center</organization>
      <email>bible.keith@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

